Abstract
Seven inoperable patients with tracheal neoplasms received a high dose rate (HDR) brachytherapy boost (median 15 Gy, single dose 3-5 Gy) for residual tumour after external beam radiotherapy (median 50 Gy, 5 x 2 Gy/week). The median actuarial survival was 34.3 months. The 1-, 2- and 3-year actuarial survival rates were 85.7%, 85.7% and 32%. Local control was obtained in 5/7 patients. Late toxicity occurred in three patients (stenosis n = 2, hemorrhage n = 1). Our data indicate, that a HDR brachytherapy boost is effective and feasible.
MeSH terms
-
Actuarial Analysis
-
Adult
-
Aged
-
Brachytherapy / adverse effects
-
Brachytherapy / methods*
-
Bronchoscopy
-
Carcinoma, Adenoid Cystic / radiotherapy
-
Carcinoma, Adenoid Cystic / surgery
-
Carcinoma, Squamous Cell / radiotherapy
-
Carcinoma, Squamous Cell / surgery
-
Chondrosarcoma / radiotherapy
-
Chondrosarcoma / surgery
-
Disease Progression
-
Feasibility Studies
-
Female
-
Follow-Up Studies
-
Hemorrhage / etiology
-
Humans
-
Laser Coagulation
-
Male
-
Middle Aged
-
Neoplasm Invasiveness
-
Neoplasm, Residual / radiotherapy
-
Radiation Injuries / etiology
-
Radiotherapy Dosage
-
Radiotherapy, High-Energy
-
Remission Induction
-
Survival Rate
-
Tomography, X-Ray Computed
-
Tracheal Diseases / etiology
-
Tracheal Neoplasms / radiotherapy*
-
Tracheal Neoplasms / surgery
-
Tracheal Stenosis / etiology